Email
Print
Anti-Migraine Drugs Market Overview
Anti-Migraine Drugs Market Size is estimated to reach $11.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 8.3% over the forecast period of 2022-2027. A migraine is a common neurological disorder that causes throbbing, pulsating headaches on one side of the head which varies in intensity. Tetracycline which is an antibiotic that works by stopping the growth of bacteria sometimes causes acute migraine attacks besides nausea, vomiting, diarrhea, and loss of appetite. Anti-migraine drugs are used to reduce the intensity of migraine headaches. Migraine headaches are sometimes preceded by warning symptoms called aura such as flashing lights or zigzag lines. Anti-nausea drugs are advised if migraine with aura is accompanied by nausea and vomiting. Drugs containing opioids such as oxycontin, Vicodin, Percocet, and so on prevent reversal of migraine central sensitization. The medications used in migraine treatment can be split into two categories: abortive and preventive. Abortive drugs are used to stop an existing migraine attack, while preventive drugs are intended to limit the number of migraine attacks. The rising prevalence of migraines, increase in healthcare expenditure and rising awareness about anti-migraine drugs are some of the factors driving the Anti-Migraine Drugs Market growth during the forecast period 2022-2027.
Report Coverage
The report: “Anti-Migraine
Drugs Market Forecast (2022-2027)", by Industry ARC covers an in-depth
analysis of the following segments of the Anti-Migraine Drugs Market.
By Drug Type- Abortive Medications: Triptans, Ergots, and Preventive Medications: Blood pressure-lowering Medications, Anticonvulsant
Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative
Therapies
By End-User- Males and Females
By Route of
Administration: Oral
& nasal and Injectables
By Distribution
Channel- Pharmaceutical
stores, E-Commerce, and Others
By Geography- North America (U.S., Canada, Mexico),
Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest
of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New
Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest
of South America), and Rest of the World (the Middle East, and Africa).
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021 owing to the increasing adoption of anti-migraine drugs owing to the growing prevalence of migraine cases. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to the rising awareness about the effectiveness of Anti-nausea drugs containing oxycontin. The robust growth of triptan and the development of novel drugs to cure migraine is predicted to augment the market growth during the forecast period of 2022-2027.
- The increasing female population with a high risk of migraine is estimated to drive the market growth of anti-migraine drugs. Side effects of migraine and increasing competition in the market continue to pose threat to the market growth.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Anti-Migraine Drugs Market Report.
Anti-Migraine Drugs Market: Market Share (%) by Region, 2021
Anti-Migraine Drugs Market Segmentation Analysis- By Drug Type
Anti-Migraine
Drugs Market based on drug type can be further segmented into Abortive and
Preventive Medications. The sub-segment Triptans of Abortive segment held a
dominant market share in the year 2021 and is estimated to be the fastest-growing,
with a CAGR of 6.4% over the forecast period of 2022-2027. Anti-nausea drugs
work by relaxing hyperactive nerves in the brain, which are triggered by
migraines. They also aid in the stabilization of blood vessels. This aids in
the relief of migraine symptoms. Oral triptans are better than oral ergots
because the bioavailability oral of ergotamine is extremely low.
Bioavailability is the ability of a drug or other substance to be absorbed and
used by the body. Triptans are highly effective, lessens symptoms, or aborts an
attack in 70–80% of patients within 30–90 minutes. Those with a history of, or
risk factors for, heart disease, high blood pressure, high cholesterol,
impaired liver function, stroke, or diabetes should avoid triptans. Increasing
healthcare expenditure is estimated to propel market growth during the
forecast period.
Anti-Migraine Drugs Market Segmentation Analysis- By End User
Anti-Migraine
Drugs Market based on end-user can be further segmented into Males and
Females. Females held a dominant market share in the year 2021 and are estimated
to be the fastest-growing, with a CAGR of 5.9% over the forecast period of
2022-2027. According to Migraine Research Foundation, Women are three times
more likely than males to suffer from migraines. In the U.S., 18% of women
suffer from migraine compared to 6% of men. Hormonal changes are estimated to
be the cause of migraines in approximately 70% of women. Estrogen is a hormone
that regulates the female reproductive system as well as controls the chemicals
in the brain that affect pain sensation. A drop in the level of estrogen can result
in a headache, usually in the form of a migraine that lasts four to 72 hours.
Usually, hormone fluctuations occur before menstruation, during pregnancy, after
giving birth, during perimenopause and menopause, at times of anxiety and
stress. The rising female population is predicted to augment the market growth of
anti-migraine drugs over the forecast period 2022-2027.
Anti-Migraine
Drugs Market Segmentation Analysis- By Geography
The Anti-Migraine
Drugs market based on Geography can be further segmented into North America,
Europe, Asia-Pacific, South America, and the Rest of the World. North America
held a dominant market share of 41% in the year 2021 as compared to the other
counterparts on account of the rising prevalence of migraine and increasing
adoption of anti-migraine drugs & Anti-nausea drugs. According
to American Migraine Association, migraine impacts over 37 million men, women, and children in the USA. One in four households has a member with migraine.
However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR of 6.2% over the forecast period of 2022-2027 on account of an increase in demand for better healthcare facilities, raising awareness about the effectiveness of anti-migraine drugs, untapped investment potential, and rising prevalence of migraine. China is dominating and is estimated to dominate during the forecast period the Asia-Pacific migraine treatment market owing to its fastest-growing pharmaceutical industry. China’s government’s pharma policies and incentives devoted towards the reformation of the pharmaceutical industry are estimated to augment the market growth over the forecast period.
Anti-Migraine Drugs Market Drivers
The Increasing Prevalence of Migraine has benefitted the consumption of anti-migraine
drugs
According to the
World Health Organization (WHO), present migraine affects 10% of individuals
worldwide, while lifetime migraine affects 1 in every 7 adults. Approximately
3000 migraine attacks per million persons worldwide occur every day and it is
ranked as the 19th most common reason for disability by WHO. Factors
such as increasing work pressure, anxiety, stress, and changes in lifestyles are
some of the causes for the increasing prevalence of migraine globally. According to
the American Migraine Foundation, if one of the parents has migraines, the
child has a 50% chance of developing migraines as well. If both
the parents suffer from migraine, chances increase to 75 percent. Migraines
are primarily caused by a combination of genetic, environmental, and lifestyle
factors. Migraines are painful, but for some people, auras associated with
severe migraines may be a warning sign of a more serious problem, for instance,
an increased risk of stroke, thereby driving the Anti-Migraine Drugs Industry.
Increased
awareness of the Anti-migraine drug has readily aided the market growth.
The rise in
public awareness regarding the use of anti-migraine drugs, as well as the
expanding migraine population, are propelling the market for anti-migraine
drugs forward. Many organizations are working towards spreading awareness about
Anti-nausea drugs globally. For instance, in June 2021, the Coalition for
Headache and Migraine Patients (CHAMP) organized National Migraine &
Headache Awareness Month (MHAM) covering various aspects of migraine and its remedies.
The National Headache Foundation, USA, a leader in headache and migraine
awareness, launched its primary care migraine app where they collected the most
comprehensive information on headache disorder and migraine disease and made
them freely available to the public to raise awareness about it. The rapid
penetration of medical services into rural regions and an increase in the
development of novel drugs through R&D are estimated to augment the market
growth during the forecast period of 2022-2027.
Anti-Migraine Drugs Market Challenges
Side Effects of Anti
Migraine Drugs are impeding the market growth.
The side effects
of anti-migraine drugs continue to pose threat to the market growth. Some of the
common side effects are dizziness, drowsiness, feeling weak or tired, flushing,
nausea, and so on. People who take migraine medication too often may find that
their migraines getting worse and more frequent. Overuse of migraine medicines
might result in a headache called Medication-Overuse Headache (MOH) or Rebound
Headaches. The risk of getting a medication-overuse headache is considerably
higher when these drugs are taken frequently over a long period of time which
is at least three months than when they are taken over a shorter period of
time. Also, some of the anti-migraine
drugs are not advised for people having a history of, or risk factors for,
heart disease, high blood pressure, high cholesterol, impaired liver function,
stroke, and so on as they temporarily narrow blood vessels restrain the Anti-Migraine
Drugs market demand.
Anti-Migraine Drugs Market Competitive Landscape
Product launches,
mergers and acquisitions, joint ventures, and geographical expansions are key
strategies adopted by players in the Anti-Migraine Drugs Market. The top 10-
Anti-Migraine Drugs Market companies are-
- Eli Lilly
- GlaxoSmithKline Plc
- AbbVie Pharmaceuticals
- Impax Laboratories Inc.
- Amgen
- Lundbeck
- Bristol-Myers Squibb Company
- Pfizer Inc
- AstraZeneca plc
- Endo International Inc
Recent Developments
- In September 2021, FDA approved QULIPTA, the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine by AbbVie Pharmaceuticals. CGRP and its receptors are found in areas of the nervous system linked to migraine pathogenesis, and CGRP levels have been found to be higher during migraine attacks in studies. QULIPTA is a once-daily dose that blocks CGRP and comes in three strengths: 10 mg, 30 mg, and 60 mg.
- In June 2021, Amgen announced the Approval of Aimovig (Erenumab) in Japan for The Suppression of Onset of Migraine Attacks in Adults by the Japanese Ministry of Health, Labour, and Welfare. It is Japan's First and Only Approved Treatment for Blocking the Calcitonin Gene-Related Peptide Receptor (CGRP-R), which is involved in migraine.
- In October 2019, Lundbeck, a Danish global pharmaceutical business, acquired Alder BioPharmaceuticals, a pharmaceutical development company situated in Bothell, Washington. A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval in February 2020. The drug blocks calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain
Relevant Titles
Report Code: HCR 0217
Anti-Hypertensive
Drugs Market
Report Code: HCR 0148